Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Jw Pharmaceutical Corporation (001060:KRX), powered by AI.
Jw Pharmaceutical Corporation is currently trading at ₩30,250. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Jw Pharmaceutical Corporation on Alpha Lenz.
Jw Pharmaceutical Corporation's P/E ratio is 10.7.
“Jw Pharmaceutical Corporation trades at a P/E of 10.7 (undervalued) with strong ROE of 21.9%.”
Ask for details →Jw Pharmaceutical Corporation is a leading healthcare company engaged in the development, manufacture, and distribution of pharmaceutical products. With a strong focus on innovation and quality, this corporation plays a pivotal role in the pharmaceutical industry by providing a broad array of medicines that address diverse medical needs. The company specializes in pharmaceuticals for cardiovascular, gastrointestinal, and metabolic disorders, including antibiotics and anti-cancer drugs. Additionally, Jw Pharmaceutical is involved in the research and development of advanced pharmaceuticals and biotechnology products, contributing to the expansion of medical solutions on a global scale. This company not only serves the healthcare market with its extensive product line but also collaborates with various international firms to bring cutting-edge medical therapies to different regions. Through its dedication to improving health and well-being, Jw Pharmaceutical Corporation maintains its significance in the pharmaceutical market by continuously adapting to the ever-evolving landscape of healthcare needs.
“Jw Pharmaceutical Corporation trades at a P/E of 10.7 (undervalued) with strong ROE of 21.9%.”
Ask for details →Jw Pharmaceutical Corporation (ticker: 001060) is a company listed on KRX in the Healthcare sector (Drug Manufacturers - Specialty & Generic). It has approximately 1,048 employees. Market cap is $704.4B.
The current price is ₩30,250 with a P/E ratio of 10.69x and P/B of 2.11x.
ROE is 21.86% and operating margin is 11.50%. Annual revenue is $719.4B.